Company Profile

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Employees

Sector

Biotechnology & Medical Research

More about the company

24/24/24	CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	CI
13/24/13	Senti Biosciences, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	CI
15/23/15	Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	CI
27/23/27	Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	CI
12/22/12	Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	CI
23/22/23	Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	CI
16/21/16	Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	CI
18/21/18	Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	CI
12/21/12	CombiGene in Billion-Dollar Deal with Spark Therapeutics	CI
07/21/07	NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	CI
21/21/21	Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	CI
13/21/13	Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	CI
25/21/25	Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer	CI

11/23/11	One of Nature’s journals publishes article about CombiGene’s epilepsy project	AQ
30/23/30	Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance	AQ
30/23/30	Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders	AQ
17/22/17	Watch CEO Jan Nilsson’s presentation at Aktiedagen Göteborg	AQ
10/22/10	CombiGene presents at Aktiedagen Göteborg on Monday 16 May	AQ

12/22/12	Roche: Gentherapie SPK-8011 von Tochter Spark erweist sich als dauerhaft wirksam
18/19/18	Roche-Chef will aus Spark ein Exzellenzzentrum für Gentherapie machen
17/19/17	Roche exécute son offre sur Spark Therapeutics
17/19/17	Spark Therapeutics : Roche finalise son acquisition
17/19/17	Roche officialise la finalisation de la reprise de Spark Therapeutics

Manager	Title	Age	Since
Sylke Poehling CEO	Chief Executive Officer	-	09/09/2024
Michael Retterath PRN	Corporate Officer/Principal	-	16/11/2020

Director	Title	Age	Since
Bruce Resnick BRD	Director/Board Member	-	17/12/2019
Sean Johnston BRD	Director/Board Member	-	17/12/2019

Spark Therapeutics, Inc. Share Price

Stocks

US84652J1034

Biotechnology & Medical Research

Latest news: Spark Therapeutics, Inc.

Press Releases: Spark Therapeutics, Inc.

News in other languages: Spark Therapeutics, Inc.

Managers and Directors: Spark Therapeutics, Inc.

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPARK THERAPEUTICS, INC.	-.--%	-.--%	-	-	437.51Cr
WUXI APPTEC CO., LTD.	-4.10%	-8.54%	+40.05%	+66.99%	6.33TCr
ARGENX SE	+0.03%	+7.75%	+11.27%	+73.87%	5.49TCr
LONZA GROUP AG	+0.67%	+4.64%	+10.10%	+92.92%	5.33TCr
IQVIA HOLDINGS INC.	+0.61%	+2.69%	+27.75%	+50.97%	4.58TCr
BEONE MEDICINES AG	-1.08%	+2.19%	+21.92%	+131.38%	4.35TCr
REVOLUTION MEDICINES, INC.	-3.39%	-0.83%	+254.27%	+571.04%	4.02TCr
CELLTRION, INC.	-1.67%	+6.70%	+14.42%	+56.67%	3.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.76%	2.37TCr
GENMAB A/S	-0.38%	+5.52%	+36.22%	+27.35%	2.38TCr
Average	-0.81%	+0.46%	+49.45%	+118.94%	4.24TCr
Weighted average by Cap.	-1.07%	+0.59%	+47.59%	+122.53%